Skip to main content
Institutional profile

Veracyte

Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.

  • Genetic Testing & Genomics Providers

Overview

Veracyte is a genomic diagnostics company focused on resolving diagnostic uncertainty and guiding care in selected disease areas. Its platform includes genomic classifiers and molecular tests used in fields such as thyroid cancer, prostate cancer, breast cancer, lung cancer, and interstitial lung disease.

The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.

Veracyte is included in 2 2026 ranking categories. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identityVeracyte
Formation history2006 — incorporated as Calderome; renamed Veracyte in 2008
Institution typeGenetic Testing & Genomics Providers institution
HeadquartersSouth San Francisco, United States
Primary focusGenetic Testing & Genomics Providers

Principal activities

The company’s importance lies in clinical decision support. Some genetic and genomic tests are not broad sequencing panels but disease-specific classifiers designed to clarify whether surgery, biopsy, surveillance, or treatment is appropriate. This type of genomic diagnostic can influence care pathways even when it is narrower than comprehensive genomic profiling.

Core capability

Genetic Testing & Genomics Providers

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Genetic Testing & Genomics Providers

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Veracyte’s focused test portfolio, clinical utility orientation, and role in specialty decision-making support its inclusion among established genetic testing and genomics providers.

Veracyte is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Veracyte should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Veracyte. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationVeracyte
HeadquartersSouth San Francisco, United States
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Additional published ranking appearances

These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.

Published rankingEdition / tierAssessed business
Top 20 Precision Medicine Diagnostics Providers 20252025 · Tier IIVeracyte
Top 20 Genetic Testing & Genomics Providers 20252025 · Tier IIVeracyte
Top 20 Precision Medicine Diagnostics Providers 20242024 · Tier IIVeracyte
Top 20 Genetic Testing & Genomics Providers 20242024 · Tier IIVeracyte
Top 20 Precision Medicine Diagnostics Providers 20232023 · Tier IIVeracyte
Top 20 Genetic Testing & Genomics Providers 20232023 · Tier IIVeracyte

Veracyte is a molecular cancer-diagnostics company headquartered in South San Francisco, California. Veracyte and Veracyte Inc refer to the same business; diagnostic-product assessments and employer assessments retain their separate scope.

Primary sources: company reference 1.

Assessed business: Veracyte Inc

Veracyte Inc is profiled in The Economy Rankings across Employers for Research & Innovation Careers, Pharmaceutical & Biotechnology Employers, Employers for Organizational Trust.

Business-specific facts retained from the earlier Veracyte Inc assessment; dates and locations refer to that business scope.

Assessed U.S. headquarters / baseSan Diego, CA, US
Reported business origins2008

The category profiles below describe the named businesses, products, programmes or employee groups assessed in the linked rankings. Their scope follows each source.

Top 30 Employers for Organizational Trust 2027 — Veracyte Inc

Veracyte combines biological assay development and genomic diagnostics with laboratory, research and bioinformatics work. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This establishes an employment mechanism alongside the technical roles, while biological testing and assay research place the employer within the biotechnology scope rather than treating it as a general software vendor.

Great Place To Work’s U.S. profile, updated November 2025, reports 90% overall workplace endorsement. A published employee item records 93% agreement: “Management is honest and ethical in its business practices.”

  • Employing entity / assessed group: Veracyte Inc (assessed U.S. employing group)
  • Assessed workforce: U.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded.
  • Assessed U.S. headquarters / base: San Diego, CA, US
  • Reported business origins: 2008

Top 30 Employers for Research & Innovation Careers 2027 — Veracyte Inc

Veracyte’s scientific employment spans biological assay research, laboratory work and bioinformatics. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This links identifiable scientific disciplines with an operating employee mechanism, rather than treating genomic technology or diagnostic accuracy alone as evidence of an attractive research career.

The combination is relevant to work that draws on both biological and analytical expertise. The filing and careers record establish actual professional roles and development support, while the US employee evidence supplies wider organizational context. It does not establish identical experiences across research, commercial and office functions, or show that every community participant progresses to a more senior role.

  • Assessed workforce: US employees in documented scientific/research-development work and professional support; role and programme eligibility applies.

Top 30 Pharmaceutical & Biotechnology Employers 2027 — Veracyte Inc

Veracyte combines biological assay development and genomic diagnostics with laboratory, research and bioinformatics work. Its workforce filing describes employee-led communities supporting professional development, connection and engagement. This establishes an employment mechanism alongside the technical roles, while biological testing and assay research place the employer within the biotechnology scope rather than treating it as a general software vendor.

Great Place To Work’s U.S. profile, updated November 2025, reports 90% overall workplace endorsement. A published employee item records 93% agreement: “Management is honest and ethical in its business practices.”

RankingEdition / classificationAssessed scope
Employers for Research & Innovation Careers2027 · Tier I · position 5US employees in documented scientific/research-development work and professional support; role and programme eligibility applies.
Pharmaceutical & Biotechnology Employers2027 · Tier IIIU.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded.
Employers for Organizational Trust2027 · Tier IIU.S. directly employed workforce in provider cohort; contractors and unassessed foreign affiliates excluded.

Rankings and recognition

2026

Tier II

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Genetic Testing & Genomics Providers 2026 — 2026 inclusion and tier classification.
  2. Healthcare Ranking — Top 30 Precision Medicine Diagnostics Providers 2026 — 2026 inclusion and tier classification.
  3. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  4. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  5. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Genetic Testing & Genomics Providers

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status.